Cargando…

Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.

We attempted to clarify whether serum levels of a carboxy-terminal fragment of ProGRP, ProGRP(31-98), could serve as a more accurate tumour marker in patients with SCLC than neuron-specific enolase (NSE). ProGRP(31-98) and NSE were measured retrospectively in 101 newly diagnosed untreated patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Takada, M., Kusunoki, Y., Masuda, N., Matui, K., Yana, T., Ushijima, S., Iida, K., Tamura, K., Komiya, T., Kawase, I., Kikui, N., Morino, H., Fukuoka, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074511/
https://www.ncbi.nlm.nih.gov/pubmed/8630283
_version_ 1782137982603493376
author Takada, M.
Kusunoki, Y.
Masuda, N.
Matui, K.
Yana, T.
Ushijima, S.
Iida, K.
Tamura, K.
Komiya, T.
Kawase, I.
Kikui, N.
Morino, H.
Fukuoka, M.
author_facet Takada, M.
Kusunoki, Y.
Masuda, N.
Matui, K.
Yana, T.
Ushijima, S.
Iida, K.
Tamura, K.
Komiya, T.
Kawase, I.
Kikui, N.
Morino, H.
Fukuoka, M.
author_sort Takada, M.
collection PubMed
description We attempted to clarify whether serum levels of a carboxy-terminal fragment of ProGRP, ProGRP(31-98), could serve as a more accurate tumour marker in patients with SCLC than neuron-specific enolase (NSE). ProGRP(31-98) and NSE were measured retrospectively in 101 newly diagnosed untreated patients with SCLC, 111 with non-small-cell lung cancer (NSCLC) and 114 patients with non-malignant lung diseases. ProGRP(31-98) and NSE levels were determined using a sandwich enzyme-linked immunosorbent assay. Sensitivity in SCLC patients was 72.3% for ProGRP(31-98) and 62.4% for NSE. Comparing the area under curve (AUC) of 'receiver operator characteristics' of ProGRP(31-98) with that of NSE, ProGRP(31-98) was the more powerful marker in the diagnosis of SCLC (P = 0.0001). Serum levels of ProGRP(31-98) were higher in the 40 patients with extensive disease than in the 61 patients with limited disease (P = 0.0082). ProGRP(31-98) was significantly higher in patients with pure small-cell carcinoma than in patients with mixed small-cell/large-cell carcinoma (P = 0.02). In serial measurement in 16 patients responding to treatment, a high degree of correlation was noted between the decrease in serum ProGRP(31-98) levels and clinical response during the second week after treatment (P = 0.0045). These results indicate that the determination of serum ProGRP(31-98) levels plays an important role in the diagnosis and treatment of SCLC patients.
format Text
id pubmed-2074511
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20745112009-09-10 Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. Takada, M. Kusunoki, Y. Masuda, N. Matui, K. Yana, T. Ushijima, S. Iida, K. Tamura, K. Komiya, T. Kawase, I. Kikui, N. Morino, H. Fukuoka, M. Br J Cancer Research Article We attempted to clarify whether serum levels of a carboxy-terminal fragment of ProGRP, ProGRP(31-98), could serve as a more accurate tumour marker in patients with SCLC than neuron-specific enolase (NSE). ProGRP(31-98) and NSE were measured retrospectively in 101 newly diagnosed untreated patients with SCLC, 111 with non-small-cell lung cancer (NSCLC) and 114 patients with non-malignant lung diseases. ProGRP(31-98) and NSE levels were determined using a sandwich enzyme-linked immunosorbent assay. Sensitivity in SCLC patients was 72.3% for ProGRP(31-98) and 62.4% for NSE. Comparing the area under curve (AUC) of 'receiver operator characteristics' of ProGRP(31-98) with that of NSE, ProGRP(31-98) was the more powerful marker in the diagnosis of SCLC (P = 0.0001). Serum levels of ProGRP(31-98) were higher in the 40 patients with extensive disease than in the 61 patients with limited disease (P = 0.0082). ProGRP(31-98) was significantly higher in patients with pure small-cell carcinoma than in patients with mixed small-cell/large-cell carcinoma (P = 0.02). In serial measurement in 16 patients responding to treatment, a high degree of correlation was noted between the decrease in serum ProGRP(31-98) levels and clinical response during the second week after treatment (P = 0.0045). These results indicate that the determination of serum ProGRP(31-98) levels plays an important role in the diagnosis and treatment of SCLC patients. Nature Publishing Group 1996-05 /pmc/articles/PMC2074511/ /pubmed/8630283 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Takada, M.
Kusunoki, Y.
Masuda, N.
Matui, K.
Yana, T.
Ushijima, S.
Iida, K.
Tamura, K.
Komiya, T.
Kawase, I.
Kikui, N.
Morino, H.
Fukuoka, M.
Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
title Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
title_full Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
title_fullStr Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
title_full_unstemmed Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
title_short Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
title_sort pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074511/
https://www.ncbi.nlm.nih.gov/pubmed/8630283
work_keys_str_mv AT takadam progastrinreleasingpeptide3198asatumourmarkerofsmallcelllungcancercomparativeevaluationwithneuronspecificenolase
AT kusunokiy progastrinreleasingpeptide3198asatumourmarkerofsmallcelllungcancercomparativeevaluationwithneuronspecificenolase
AT masudan progastrinreleasingpeptide3198asatumourmarkerofsmallcelllungcancercomparativeevaluationwithneuronspecificenolase
AT matuik progastrinreleasingpeptide3198asatumourmarkerofsmallcelllungcancercomparativeevaluationwithneuronspecificenolase
AT yanat progastrinreleasingpeptide3198asatumourmarkerofsmallcelllungcancercomparativeevaluationwithneuronspecificenolase
AT ushijimas progastrinreleasingpeptide3198asatumourmarkerofsmallcelllungcancercomparativeevaluationwithneuronspecificenolase
AT iidak progastrinreleasingpeptide3198asatumourmarkerofsmallcelllungcancercomparativeevaluationwithneuronspecificenolase
AT tamurak progastrinreleasingpeptide3198asatumourmarkerofsmallcelllungcancercomparativeevaluationwithneuronspecificenolase
AT komiyat progastrinreleasingpeptide3198asatumourmarkerofsmallcelllungcancercomparativeevaluationwithneuronspecificenolase
AT kawasei progastrinreleasingpeptide3198asatumourmarkerofsmallcelllungcancercomparativeevaluationwithneuronspecificenolase
AT kikuin progastrinreleasingpeptide3198asatumourmarkerofsmallcelllungcancercomparativeevaluationwithneuronspecificenolase
AT morinoh progastrinreleasingpeptide3198asatumourmarkerofsmallcelllungcancercomparativeevaluationwithneuronspecificenolase
AT fukuokam progastrinreleasingpeptide3198asatumourmarkerofsmallcelllungcancercomparativeevaluationwithneuronspecificenolase